SAB Biotherapeutics
SAB Biotherapeutics
SABS
NASDAQ
1.60
USD
0.00%
About
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach.
Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases.
The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 11.5K |
| Three Month Average Volume | 215.7K |
| High Low | |
| Fifty-Two Week High | 10.5 USD |
| Fifty-Two Week Low | 2.16 USD |
| Fifty-Two Week High Date | 30 Oct 2023 |
| Fifty-Two Week Low Date | 14 Aug 2024 |
| Price and Volume | |
| Current Price | 2.94 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 7.03% |
| Thirteen Week Relative Price Change | 4.05% |
| Twenty-Six Week Relative Price Change | -39.37% |
| Fifty-Two Week Relative Price Change | -67.41% |
| Year-to-Date Relative Price Change | -63.89% |
| Price Change | |
| One Day Price Change | 1.38% |
| Thirteen Week Price Change | 11.36% |
| Twenty-Six Week Price Change | -33.33% |
| Five Day Price Change | 10.53% |
| Fifty-Two Week Price Change | -59.17% |
| Year-to-Date Price Change | -57.24% |
| Month-to-Date Price Change | 5.94% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 6.21099 USD |
| Book Value Per Share (Most Recent Quarter) | 4.99712 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 6.21099 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 4.99712 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -5.30501 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.4055 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.36462 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -7.64174 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -5.6909 USD |
| Normalized (Last Fiscal Year) | -7.64174 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -7.64174 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -5.6909 USD |
| Including Extraordinary Items (Last Fiscal Year) | -7.64174 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -5.6909 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 6.1315 USD |
| Cash Per Share (Most Recent Quarter) | 4.04431 USD |
| Cash Flow Per Share (Last Fiscal Year) | -6.92578 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -4.61517 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -4.90746 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -1,346 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,450.32% |
| Pretax Margin (Last Fiscal Year) | -1,884.50% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,700.56% |
| Operating Margin (Trailing Twelve Months) | -1,647.03% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,884.50% |
| Net Profit Margin (Trailing Twelve Months) | -1,450.32% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 207.69% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -56.68% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -65.65% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 41.92% |
| EPS Change (Trailing Twelve Months) | 8.50% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -33,224,490 |
| Net Debt (Last Fiscal Year) | -51,964,740 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 12 |
| Price to Sales (Trailing Twelve Months) | 10 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 6 |
| Long Term Debt to Equity (Most Recent Quarter) | 7 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -25,316,560 |
| Free Cash Flow (Trailing Twelve Months) | -37,417,090 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 8 |
| Total Debt to Equity (Most Recent Quarter) | 9 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -62.58% |
| Return on Assets (Trailing Twelve Months) | -82.85% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -95.51% |
| Return on Equity (Trailing Twelve Months) | -122.49% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -77.39% |
| Return on Investment (Trailing Twelve Months) | -102.37% |
| Return on Investment (5 Year) | -99,999.99% |